Vibegron for ENergy Thinking and Resilience in Aging

Part of paid clinical trials in Winston-Salem, North Carolina.

Sponsor
Wake Forest University Health Sciences
Study ID
NCT06987383
Phase
PHASE3
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
45 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Vibegron — DRUG
    A drug in a class of medications called beta-3 adrenergic agonists; approved for use with Overactive Bladder; 75mg tablets will be used in this study
  • Placebo — DRUG
    Tablets made of inert substance that looks like the vibegron tablets but has no therapeutic value

Study Details

This 12-week randomized, double-blind, placebo-controlled trial will test the hypothesis that Vibegron (brand name GEMTESA) can improve energy metabolism, cardiometabolic risk factors, and physical and cognitive function in middle-aged and older adults with obesity.

Key Dates

Start date
Aug 31, 2026
Status verified
Feb 2026
Primary completion
Jul 31, 2028
Completion
Jul 31, 2028

Study Design

Enrollment
40 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Vibegron
    Participants in this arm will take 75mg/day Vibegron for 12 weeks.
  • Placebo Comparator: Placebo
    Participants in this arm will take placebo daily for 12 weeks.

Primary Outcome Measure

Resting Metabolic Rate [ Time Frame: Baseline ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Wake Forest University Health SciencesWinston-SalemNorth Carolina27157
Tina E Brinkley, PhD
336-713-8534
Tina E Brinkley, PhD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Winston-Salem, NC

Related Studies